Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ovid Makes Two New Appointments

This article was originally published in Scrip

Executive Summary

Ovid Therapeutics has appointed Amit Rakhit chief medical and portfolio management officer and Daniel H. Geschwind to the company's scientific advisory board. Prior to Ovid, Rakhit was senior vice president, head of worldwide medical at Biogen and he was also vice president, program leadership and management at Biogen. Previously he held leadership roles at Bristol-Myers Squibb including director, cardiovascular R&D and executive medical director, cardiovascular/metabolics. Recently Geschwind was appointed senior associate dean and associate vice chancellor of precision medicine in the UCLA Health System and David Geffen School of Medicine. He is a professor of neurology and psychiatry and biobehavioral sciences at the UCLA School of Medicine and director of the Center for Autism Research and Treatment (CART) and co-director of the center for neurobehavioral genetics at UCLA.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC064980

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel